Evolution of cell therapy for renal cell carcinoma
Abstract Treatment for renal cell carcinoma (RCC) has improved dramatically over the last decade, shifting from high-dose cytokine therapy in combination with surgical resection of tumors to targeted therapy, immunotherapy, and combination therapies. However, curative treatment, particularly for adv...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-01-01
|
| Series: | Molecular Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12943-023-01911-x |
| _version_ | 1827382409014804480 |
|---|---|
| author | Yufei Wang Eloah Rabello Suarez Gabriella Kastrunes Najla Santos Pacheco de Campos Rabia Abbas Renata Schmieder Pivetta Nithyassree Murugan Ghanbar Mahmoodi Chalbatani Vincent D’Andrea Wayne A. Marasco |
| author_facet | Yufei Wang Eloah Rabello Suarez Gabriella Kastrunes Najla Santos Pacheco de Campos Rabia Abbas Renata Schmieder Pivetta Nithyassree Murugan Ghanbar Mahmoodi Chalbatani Vincent D’Andrea Wayne A. Marasco |
| author_sort | Yufei Wang |
| collection | DOAJ |
| description | Abstract Treatment for renal cell carcinoma (RCC) has improved dramatically over the last decade, shifting from high-dose cytokine therapy in combination with surgical resection of tumors to targeted therapy, immunotherapy, and combination therapies. However, curative treatment, particularly for advanced-stage disease, remains rare. Cell therapy as a “living drug” has achieved hematological malignancy cures with a high response rate, and significant research efforts have been made to facilitate its translation to solid tumors. Herein, we overview the cellular therapies for RCC focusing on allogeneic hematopoietic stem cell transplantation, T cell receptor gene-modified T cells, chimeric antigen receptor (CAR) T cells, CAR natural killer (NK) cells, lymphokine-activated killer (LAK) cells, γδ T cells, and dendritic cell vaccination. We have also included perspectives for using other recent approaches, such as CAR macrophages, dendritic cell-cytokine induced killer cells and regulatory CAR-T cells to shed light on preclinical development of cell therapy and advancing cell therapy into clinic to achieve cures for RCC. |
| first_indexed | 2024-03-08T14:19:08Z |
| format | Article |
| id | doaj.art-739362afabd24506afe9b7a84c657831 |
| institution | Directory Open Access Journal |
| issn | 1476-4598 |
| language | English |
| last_indexed | 2024-03-08T14:19:08Z |
| publishDate | 2024-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Molecular Cancer |
| spelling | doaj.art-739362afabd24506afe9b7a84c6578312024-01-14T12:13:49ZengBMCMolecular Cancer1476-45982024-01-0123112110.1186/s12943-023-01911-xEvolution of cell therapy for renal cell carcinomaYufei Wang0Eloah Rabello Suarez1Gabriella Kastrunes2Najla Santos Pacheco de Campos3Rabia Abbas4Renata Schmieder Pivetta5Nithyassree Murugan6Ghanbar Mahmoodi Chalbatani7Vincent D’Andrea8Wayne A. Marasco9Department of Cancer Immunology and Virology, Dana-Farber Cancer InstituteCenter for Natural and Human Sciences, Federal University of ABCDepartment of Cancer Immunology and Virology, Dana-Farber Cancer InstituteCenter for Natural and Human Sciences, Federal University of ABCDepartment of Cancer Immunology and Virology, Dana-Farber Cancer InstituteCenter for Natural and Human Sciences, Federal University of ABCDepartment of Cancer Immunology and Virology, Dana-Farber Cancer InstituteDepartment of Immunology, Mayo ClinicDepartment of Surgery, Brigham and Women’s HospitalDepartment of Cancer Immunology and Virology, Dana-Farber Cancer InstituteAbstract Treatment for renal cell carcinoma (RCC) has improved dramatically over the last decade, shifting from high-dose cytokine therapy in combination with surgical resection of tumors to targeted therapy, immunotherapy, and combination therapies. However, curative treatment, particularly for advanced-stage disease, remains rare. Cell therapy as a “living drug” has achieved hematological malignancy cures with a high response rate, and significant research efforts have been made to facilitate its translation to solid tumors. Herein, we overview the cellular therapies for RCC focusing on allogeneic hematopoietic stem cell transplantation, T cell receptor gene-modified T cells, chimeric antigen receptor (CAR) T cells, CAR natural killer (NK) cells, lymphokine-activated killer (LAK) cells, γδ T cells, and dendritic cell vaccination. We have also included perspectives for using other recent approaches, such as CAR macrophages, dendritic cell-cytokine induced killer cells and regulatory CAR-T cells to shed light on preclinical development of cell therapy and advancing cell therapy into clinic to achieve cures for RCC.https://doi.org/10.1186/s12943-023-01911-xImmunotherapyCell therapyRenal cell carcinoma (RCC)CAR-TCAR-NK |
| spellingShingle | Yufei Wang Eloah Rabello Suarez Gabriella Kastrunes Najla Santos Pacheco de Campos Rabia Abbas Renata Schmieder Pivetta Nithyassree Murugan Ghanbar Mahmoodi Chalbatani Vincent D’Andrea Wayne A. Marasco Evolution of cell therapy for renal cell carcinoma Molecular Cancer Immunotherapy Cell therapy Renal cell carcinoma (RCC) CAR-T CAR-NK |
| title | Evolution of cell therapy for renal cell carcinoma |
| title_full | Evolution of cell therapy for renal cell carcinoma |
| title_fullStr | Evolution of cell therapy for renal cell carcinoma |
| title_full_unstemmed | Evolution of cell therapy for renal cell carcinoma |
| title_short | Evolution of cell therapy for renal cell carcinoma |
| title_sort | evolution of cell therapy for renal cell carcinoma |
| topic | Immunotherapy Cell therapy Renal cell carcinoma (RCC) CAR-T CAR-NK |
| url | https://doi.org/10.1186/s12943-023-01911-x |
| work_keys_str_mv | AT yufeiwang evolutionofcelltherapyforrenalcellcarcinoma AT eloahrabellosuarez evolutionofcelltherapyforrenalcellcarcinoma AT gabriellakastrunes evolutionofcelltherapyforrenalcellcarcinoma AT najlasantospachecodecampos evolutionofcelltherapyforrenalcellcarcinoma AT rabiaabbas evolutionofcelltherapyforrenalcellcarcinoma AT renataschmiederpivetta evolutionofcelltherapyforrenalcellcarcinoma AT nithyassreemurugan evolutionofcelltherapyforrenalcellcarcinoma AT ghanbarmahmoodichalbatani evolutionofcelltherapyforrenalcellcarcinoma AT vincentdandrea evolutionofcelltherapyforrenalcellcarcinoma AT wayneamarasco evolutionofcelltherapyforrenalcellcarcinoma |